Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11689617 | 0.85 | ALDH1A1 (0.39) | HPGDMAPTTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL11689627 | 0.85 | NPC1 (0.34) | HPGDMAPTTSHRMEN1KMT2A | |
| SCHEMBL49014 | 0.82 | — | — | |
| SCHEMBL8529532 | 0.79 | HSD17B10 (0.30) | HPGDTSHRHSD17B10KDM4EALDH1A1 | |
| SCHEMBL31170679 | 0.78 | KDM4A (0.39) | TSHRALDH1A1 | |
| SCHEMBL1558801 | 0.78 | — | — | |
| SCHEMBL10110619 | 0.78 | MEN1 (0.34) | HPGDMAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL12051314 | 0.76 | — | — | |
| Methoxyacetamide SCHEMBL11768866 | 0.74 | HPGD (0.34) | HPGDMAPTTSHRMEN1KMT2A | |
| SCHEMBL19645576 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085659-B2 | Polymer derivatives comprising an imide branching point | NEKTAR THERAPEUTICS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20120238640-A9 | Polymer Derivatives Comprising an Imide Branching Point | NEKTAR THERAPEUTICS | 2012-09-20 | — | — | US | disclosed |
| US-20080319091-A1 | Polymer Derivatives Comprising an Imide Branching Point | NEKTAR THERAPEUTICS AL, CORPORATION | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238640-A9 | Polymer Derivatives Comprising an Imide Branching Point | INCENP, ILK, PIM3 | HPGD 2834/4885MAPT 202/4885TSHR 3925/4885 |
| US-20080319091-A1 | Polymer Derivatives Comprising an Imide Branching Point | INCENP, ILK, PIM3 | HPGD 2834/4885MAPT 202/4885TSHR 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.